NCT04345913 2026-03-19
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT06360588 2026-03-19
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06400238 2026-03-19
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05490771 2026-03-18
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03789240 2026-03-03
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03939897 2025-09-24
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting